Market Intel: After A Year Of Partnerships, Insulin Pump Manufacturers Will Face Fierce Competition In 2020

 
• By Marion Webb
  
Generate a summary of this article
Listen to this article
Beta

The insulin pump market is expected to grow to $5.1bn by 2023, driven by the increasing incidence of diabetes and adoption of next-generation hybrid closed-loop systems, which allow patients and health-care providers to better manage care. This first part of a two-part series highlights the rising competitive landscape of the four major players, Medtronic, Insulet, Tandem Diabetes Care and Valeritas, with insights from endocrinologists. The second part will look at the smaller players, which are gearing up to introduce new products in 2020.

Insulin Pump for Diabetes - Illustration - Vector

The combined insulin pumps market is expected to see double-digit growth, reaching more than $5bn by 2023. Dominated by four major players and several innovative start-ups, the insulin pumps market is highly competitive and undergoing significant change. (Also see "Market Intel: Insulin Pumps Dominate $7bn-Plus Global Infusion Devices Market" - Medtech Insight, 18 May, 2018.)

While 2019 was marked by collaborations, 2020 will be the year of major product launches and heated competition. Three of...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

SpotifyApple PodcastsWebsite

More from Diabetic Care

More from Device Area

  • Owkin Teams With AstraZeneca To Develop AI-Based Breast Cancer Prescreening Tool

     
    • By Natasha Barrow

    Biopharmaceutical giant AstraZeneca has partnered with start-up “unicorn” Owkin to develop an AI-powered tool to prescreen for gBRCA mutations on the basis of morphological features in digitized pathology slides. Built on extensive, high-quality data sourced from the France-based PortrAIt consortium, the AI will help to prioritize patients for further testing, streamlining the diagnostic process, Owkin says.

  • Route 92 To Drive FreeClimb Neurointervention Sales With Extended Series F Funding

     
    • By Natasha Barrow

    An additional $50m brings the neurovascular intervention specialist’s total Series F funding to $82m. Route 92 says it will use the capital to build its sales and support teams and pursue regulatory authorizations around the globe for its FreeClimb portfolio while advancing its SUMMIT MAX clinical trial for the investigational Monopoint Reperfusion System.

  • TRiCares Initiates EU Pivotal Study For Topaz Tricuspid Valve Replacement

     
    • By Natasha Barrow

    TRiCares announced first implantation of the Topaz transfemoral tricuspid heart valve replacement system as part of the company’s EU pivotal study. If all goes to plan, the device will compete with Edwards’ Evoque system. The announcement follows the company’s $50m series D funding raise in July.